Immuron Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMRN research report →
Companywww.immuron.com.au
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver.
- CEO
- Steven George Lydeamore
- IPO
- 2017
- Employees
- 7
- HQ
- Carlton, VIC, AU
Price Chart
Valuation
- Market Cap
- $6.38M
- P/E
- -1.89
- P/S
- 1.10
- P/B
- 0.67
- EV/EBITDA
- 0.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 63.69%
- Op Margin
- -68.38%
- Net Margin
- -62.14%
- ROE
- -43.95%
- ROIC
- -29.04%
Growth & Income
- Revenue
- $7.29M · 48.63%
- Net Income
- $-5,215,987 · 24.81%
- EPS
- $-0.90 · 25.66%
- Op Income
- $-5,344,548
- FCF YoY
- -4.36%
Performance & Tape
- 52W High
- $2.39
- 52W Low
- $0.68
- 50D MA
- $0.83
- 200D MA
- $1.30
- Beta
- 0.41
- Avg Volume
- 31.90K
Get TickerSpark's AI analysis on IMRN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Palumbo Flavio | other | 0 |
| Oct 24, 24 | Palumbo Flavio | other | 640,824 |
| Mar 18, 26 | Pollock Daniel Jude | other | 0 |
| Mar 18, 26 | Pollock Daniel Jude | other | 0 |
| Dec 8, 25 | Pollock Daniel Jude | other | 333,333 |
| Nov 24, 25 | Pollock Daniel Jude | other | 1,000,000 |
| Nov 24, 24 | Brennan Paul Gerard | other | 666,667 |
| Nov 24, 25 | Brennan Paul Gerard | other | 1,000,000 |
| Mar 18, 26 | Kanellos Jerry | other | 0 |
| Oct 24, 24 | Kanellos Jerry | other | 272,134 |
Our IMRN Coverage
We haven't published any research on IMRN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMRN Report →